Rockville, Dec. 08, 2022 (GLOBE NEWSWIRE) -- The microbiome therapeutics market size is estimated at US$ 112.20 Bn in 2022 and is anticipated to grow at a CAGR of 32% from 2022 to 2032. The microbiome therapeutics market size is anticipated to reach US$ 1801.91 Billion by 2032.
Strategic partnerships for R&D, research and development, and portfolio expansion in the area of microbiome therapeutics are among the factors driving the microbiome therapeutics market growth. The COVID-19 pandemic had a negative impact on the market severely. Clinical trial research has been significantly damaged on a global scale. Target diseases are becoming more common, which is driving up demand for microbiome therapeutics.
Download Sample Copy of This Report:
https://www.factmr.com/connectus/sample?flag=S&rep_id=7844
Key Takeaways
- By 2032, it is anticipated that the application segment for C difficile infection might well contribute the largest share—33%.
- Fecal microbiota therapy (FMT) accounted for a sizeable portion of the microbiome therapeutics market during the forecast period.
- North America ruled the microbiome therapeutics market, holding the lion's share of 74% for the forecast period.
- The United States is anticipated to have a market share of more than 44% in the global market for microbiome therapeutics.
Recent Development
- Merger
2020 will mark 4D Pharma's transition to NASDAQ public company status after it merged with Longevity Acquisition Corporation. According to the agreement with Longevity, the Live Biotherapeutic created by 4D Pharma will receive support and advancement. The FDA classifies biological products that contain a live organism—such as a bacterium—and are used to treat, prevent, or cure disease as "live biotherapeutics."
- Agreement
An exclusive sales and distribution agreement between Nahdi Medical Co. and OptiBiotix Health Plc. was signed in 2022 and will go into effect in 2023. As part of a new agreement with Nahdi, the company's GoFigure and SlimBiome Medical weight management solutions will be available in the Kingdom of Saudi Arabia starting in early 2022. This will help in the fight against the obesity pandemic.
Get Customization on this Report for Specific Research Solutions:
https://www.factmr.com/connectus/sample?flag=RC&rep_id=7844
Competitive Landscape
The majority of microbiome therapeutics market participants in the microbiome therapeutics space collaborate and partner with well-known pharmaceutical companies and academic institutions. Small start-up and clinical-stage microbiome companies are utilizing venture capital to introduce novel therapeutics based on the microbiome to the global microbiome therapeutics market.
Despite a decline in overall venture capital investments, the microbiome sector saw high VC investments in 2016, raising roughly US$ 336 million. Another significant trend in the market for global microbiome therapeutics is partnerships and research collaborations.
Key Companies Profiled
- OpenBiome
- Seres Therapeutics Inc.
- 4D Pharma plc.
- Locus Biosciences, Inc.
- Enterome SA
- Finch Therapeutics Group, Inc.
- Intralytix, Inc.
- Microbiotica
- Second Genome
- Rebiotix Inc.
- Vedanta Bioscience, Inc.
The United States is predicted to capture the largest share, surpassing 44%, in the microbiome therapeutics market. Due to the early release and rapid uptake of new medications, the United States microbiome therapeutics market is expected to grow.
It is anticipated that Europe is likely to experience significant growth. Germany is a growing microbiome therapeutics market in Europe. Even though microbiome therapeutics are highly priced, favorable reimbursement policies are predicted to make treatment uptake extremely easy in the upcoming years. Additionally, funding is given to startups for the creation and study of microbiome-based products.
Get Full Access of Complete Report:
https://www.factmr.com/checkout/7844
Key Segments of Microbiome Therapeutics Industry Research
- By Type :
- FMT
- Microbiome Drugs
- By Application :
- C. difficile
- Crohn's Disease
- Inflammatory Bowel Disease
- Diabetes
The application segment for Clostridium difficile infection (CDI or C. difficile) is anticipated to experience the fastest microbiome therapeutics market growth. The increased use of fecal microbiota transplants (FMT) in the management of Clostridium difficile is credited with the microbiome therapeutics market expansion. In recurrent cases, FMT is more effective than an antibiotic in treating C difficile.
Due to increased attention to microbial changes in patients with Crohn's disease, the Crohn's disease application segment is anticipated to grow profitably over the forecast period.
North America controlled the microbiome therapeutics market by capturing the largest share. The region's prominence is mainly ascribed to its well-established research facilities for the development of novel therapeutics and its expanding target population.
Check out more related studies published by Fact.MR Research:
Peptide Based Cancer Therapeutics Market - Fact.MR’s latest report projects that the global peptide based cancer therapeutics market will surpass a valuation of US$ 11,160 Mn by 2022-end, expanding at an impressive CAGR of 9.2% during the forecast period (2017-2022).
Peptide Based Metabolic Disorders Therapeutics Market - According to Fact.MR’s research report on the global peptide based metabolic disorders therapeutics market, the market is anticipated to show a robust growth rate during the forecasted period of 2017-2022 and expected to reflect a value more than US$ 8 Bn.
Peptide Based Infection Therapeutics Market - According to Fact.MR’s research report on the global peptide based infection therapeutics market, the market is anticipated to show a robust growth rate during the forecasted period of 2017-2022 and expected to reflect a value a bit less than US$ 1.5 Bn.
Peptide Based Hematological Disorders Therapeutics Market - the global peptide based hematological disorders therapeutics market forecasts that the global peptide based hematological disorders therapeutics market will touch a value of nearly US$ 530 MN in the year 2022 and grow at a robust CAGR during the assessment period.
Peptide Based Gastrointestinal Disorders Therapeutics Market - According to the latest report published by Fact.MR, the global peptide based gastrointestinal disorders therapeutics market is set to reflect a double-digit CAGR between 2017 and 2022, to surpass a valuation of US$ 600 MN.
About Fact.MR
We are a trusted research partner of 80% of fortune 1000 companies across the globe. We are consistently growing in the field of market research with more than 1000 reports published every year. The dedicated team of 400-plus analysts and consultants is committed to achieving the utmost level of our client’s satisfaction.
Contact:
US Sales Office
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583, +353-1-4434-232
E: sales@factmr.com
Follow Us: LinkedIn | Twitter | Blog
